Navigation Links
Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
Date:9/11/2009

over the Phase I work with NXL103 and show that the product was generally well tolerated, that it shows a beneficial interaction with food, and that no dosing adjustment was required in elderly patients. Poster A1-1943 looks at the optimization of the ratio of linopristin and flopristin, the two components of NXL103. This study concludes that a dose consisting of 250mg of linopristin and 350mg of flopristin is optimal as it gives lower pharmacokinetic variability and delivers optimal ex-vivo plasma bactericidal activity in all subjects.

Poster E-1965 provides data on the in vitro activity of NXL103 against MRSA. The study concludes that NXL103 is highly active against important bacterial species of cSSSIs including community acquired MRSA and hospital acquired MRSA, supporting the further development of this novel streptogramin for indications such as cSSSI, where staphylococci are important pathogens.

NXL104

NXL104, either alone or in combination with ceftazidime, is the subject of 9 posters and one slide presentation.

Poster A1-007 covers a Phase I study in healthy volunteers looking at the effects of age and gender on the pharmacokinetics of NXL104. The study shows that NXL104 is well tolerated and that no dose adjustment is required based on age or gender.

Poster C1-1374 describes the nature of inhibition of the class A TEM-1 beta-lactamase by NXL104. Slide Presentation C1-1098 describes the high resolution crystal structure of NXL104 complexed with the extended spectrum beta-lactamase CTX-M-15 to understand the molecular details of mechanism of inhibition.

Three of the posters outline research with NXL104/ceftazidime in murine models of infection. Poster A1-006 shows that the NXL104/ceftazidime is efficacious in a pneumonia model using a strain of Klebsiella pneumoniae expressing elevated levels of AmpC beta-lactamase. Poster B-1339, shows that NXL104/ceft
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
2. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
3. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
4. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
5. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
6. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
7. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
9. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
10. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
11. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... -- Huifeng Bio-,Pharmaceutical Technology, Inc (OTC Bulletin Board: ... and pharmaceutical raw materials,for use in pharmaceutical, nutraceutical ... financial results second quarter 2008 which,ended June 30 ... markets close., Huifeng,s earnings release and related ...
... 4 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... quarterly royalty payment of approximately $2.1 million ... Memantine for the treatment of,moderate-to-severe Alzheimer,s disease. ... quarterly royalty payments on certain,sales of Memantine ...
... announced partnership, Grid Dynamics and GridGain teamed up to develop the ... ... San Francisco, CA (PRWEB) August 4, 2008 -- Following ... up to develop the largest publicly known grid scalability test for ...
Cached Biology Technology:Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud 2Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud 3
(Date:6/18/2013)... Arlington environmental engineer has been awarded a $394,300 ... ensure water quality and flow in the new ... Andrew Kruzic, UT Arlington associate professor of civil ... to add monochloramine to the water in an ... pump stations and pipelines. Adding monochloramine is widely ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... 10% of breast and ovarian cancers are familial in ... attributable to inherited mutations from the parents in genes ... mutations, PARP inhibitors, which are currently in clinical trials, ... option for personalised cancer treatment, an alternative to standard ... of these patients generate resistance to the drug and, ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... The University of Miami,s Rosenstiel School of Marine and ... E.M. Rickaby, Ph.D., as recipient of the 2009 Rosenstiel ... Fellow of Wolfson College, Rickaby works in the Department ... current research on the interaction between marine phytoplankton and ...
... of years, green plants have employed photosynthesis to capture ... A goal of scientists has been to develop an ... produce liquid fuels from carbon dioxide and water. Researchers ... Laboratory (Berkeley Lab) have now taken a critical step ...
... the sea, and are responsible for providing nearly half of ... However, unlike their counterparts on land, the marine plants ... human sight. Consequently, we are still in a very ... phytoplankton biology and ecology. In a new paper published ...
Cached Biology News:Oxford's Dr. Rosalind Rickaby receives 2009 Rosenstiel Award 2Oxford's Dr. Rosalind Rickaby receives 2009 Rosenstiel Award 3Turning sunlight into liquid fuels 2Turning sunlight into liquid fuels 3A new view of oceanic phytoplankton 2A new view of oceanic phytoplankton 3
Request Info...
Sterile, individually wrapped, 4mm Cuvettes...
versican (H-56)...
... S1 Nuclease degrades single-stranded DNA and ... Double-stranded nucleic acids (DNA:DNA, DNA:RNA or ... with extremely high concentrations of enzyme ... remove single-stranded termini from double-stranded DNA ...
Biology Products: